Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIPNASDAQ:APGENYSE:DNANASDAQ:JANX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$65.81-0.2%$64.38$52.50▼$77.00$1.43B0.55312,253 shs166,906 shsAPGEApogee Therapeutics$43.81+1.9%$39.18$26.20▼$63.50$1.98B1.38551,869 shs399,039 shsDNAGinkgo Bioworks$9.59+2.9%$7.86$5.00▼$16.85$545.52M1.251.42 million shs1.15 million shsJANXJanux Therapeutics$23.52+1.2%$26.20$22.48▼$71.71$1.38B2.96860,923 shs391,446 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals-0.15%+1.78%+12.84%-2.66%+0.49%APGEApogee Therapeutics+1.91%+6.39%+18.79%+10.30%+14.54%DNAGinkgo Bioworks+2.81%+11.85%+41.47%+55.82%-54.63%JANXJanux Therapeutics+1.20%+3.52%-2.97%-19.18%-40.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIPANI Pharmaceuticals3.6648 of 5 stars2.51.00.03.32.33.31.3APGEApogee Therapeutics2.3471 of 5 stars3.51.00.00.02.04.20.0DNAGinkgo Bioworks0.4128 of 5 stars0.81.00.00.00.62.51.3JANXJanux Therapeutics2.0591 of 5 stars3.52.00.00.01.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.00Buy$80.1321.75% UpsideAPGEApogee Therapeutics 3.00Buy$94.60115.93% UpsideDNAGinkgo Bioworks 1.67Reduce$5.77-39.88% DownsideJANXJanux Therapeutics 3.09Buy$95.25304.97% UpsideCurrent Analyst Ratings BreakdownLatest DNA, ANIP, JANX, and APGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.004/21/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$62.00 ➝ $65.004/11/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$614.38M2.32$7.58 per share8.68$19.11 per share3.44APGEApogee TherapeuticsN/AN/AN/AN/A$15.92 per shareN/ADNAGinkgo Bioworks$227.04M2.47N/AN/A$13.17 per share0.73JANXJanux Therapeutics$10.59M131.41N/AN/A$19.49 per share1.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals-$18.52M-$1.27N/A15.63N/A-3.12%21.35%7.52%8/5/2025 (Estimated)APGEApogee Therapeutics-$182.15M-$3.60N/AN/AN/AN/A-28.35%-26.98%8/11/2025 (Estimated)DNAGinkgo Bioworks-$547.03M-$9.16N/AN/AN/A-198.84%-52.35%-27.14%8/14/2025 (Estimated)JANXJanux Therapeutics-$68.99M-$1.36N/AN/AN/A-463.91%-9.29%-8.89%8/6/2025 (Estimated)Latest DNA, ANIP, JANX, and APGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025APGEApogee Therapeutics-$1.19-$0.95+$0.24-$0.95N/AN/A5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37$1.70+$0.33$0.69$179.75 million$197.12 million5/8/2025Q1 2025JANXJanux Therapeutics-$0.43-$0.38+$0.05-$0.38$0.59 millionN/A5/6/2025Q1 2025DNAGinkgo Bioworks-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/AAPGEApogee TherapeuticsN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.462.661.98APGEApogee TherapeuticsN/A15.8215.82DNAGinkgo BioworksN/A4.884.88JANXJanux TherapeuticsN/A58.4758.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%APGEApogee Therapeutics79.04%DNAGinkgo Bioworks78.63%JANXJanux Therapeutics75.39%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals11.10%APGEApogee Therapeutics42.77%DNAGinkgo Bioworks9.72%JANXJanux Therapeutics8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.66 million19.26 millionOptionableAPGEApogee Therapeutics9146.05 million26.35 millionOptionableDNAGinkgo Bioworks64058.53 million52.84 millionOptionableJANXJanux Therapeutics3059.17 million54.38 millionOptionableDNA, ANIP, JANX, and APGE HeadlinesRecent News About These CompaniesBrokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) Price Target at $95.25June 26 at 3:35 AM | americanbankingnews.comJonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price TargetJune 24 at 6:06 PM | msn.comJanux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of "Buy" by BrokeragesJune 21, 2025 | marketbeat.comJanux Therapeutics Becomes Oversold (JANX)June 20, 2025 | nasdaq.comSG Americas Securities LLC Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)June 20, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Stock Price Down 3.6% - Should You Sell?June 16, 2025 | marketbeat.comResearch Analysts Offer Predictions for JANX FY2026 EarningsJune 10, 2025 | marketbeat.comCalifornia State Teachers Retirement System Grows Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)June 8, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Shares Up 7.9% - Here's What HappenedJune 6, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Sees Significant Increase in Short InterestJune 5, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Takes $2.48 Million Position in Janux Therapeutics, Inc. (NASDAQ:JANX)June 3, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Wellington Management Group LLPJune 1, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCJune 1, 2025 | marketbeat.comTwo Sigma Investments LP Lowers Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)May 31, 2025 | marketbeat.comNuveen Asset Management LLC Sells 39,145 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)May 31, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Squarepoint Ops LLCMay 30, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Stock Price Down 4.2% - Should You Sell?May 29, 2025 | marketbeat.comMillennium Management LLC Invests $6.22 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)May 29, 2025 | marketbeat.comWhy Janux Therapeutics, Inc.’s (JANX) Stock Is Down 7.22%May 15, 2025 | aaii.comAJanux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development OfficerMay 15, 2025 | finance.yahoo.comJanux Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNA, ANIP, JANX, and APGE Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$65.81 -0.10 (-0.15%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$65.78 -0.03 (-0.05%) As of 06/26/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Apogee Therapeutics NASDAQ:APGE$43.81 +0.82 (+1.91%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$44.22 +0.41 (+0.94%) As of 08:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Ginkgo Bioworks NYSE:DNA$9.59 +0.27 (+2.92%) Closing price 06/26/2025 03:59 PM EasternExtended Trading$9.56 -0.04 (-0.39%) As of 08:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Janux Therapeutics NASDAQ:JANX$23.52 +0.28 (+1.20%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$24.23 +0.71 (+3.02%) As of 08:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
